The following papers will be presented at the ADA conference in San Francisco and published simultaneously in either The Lancet or The Lancet Diabetes & Endocrinology journals. All papers are under embargo until the stated time. Contact details for corresponding authors are provided in the Articles and linked Comments. Funding information is listed on the first page of each Article.
Embargo: 16.45hrs [UK time] / 8.45am [San Francisco time] Saturday 8th June 2019
The Lancet: Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Once the embargo lifts, please use this link as the one above will be deactivated: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31271-1/fulltext
Embargo: 16.45hrs [UK time] / 8.45am [San Francisco time] Sunday 9th June 2019
The Lancet Diabetes and Endocrinology: Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
Once the embargo lifts, please use this link as the one above will be deactivated: http://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30184-6/fulltext
Embargo: 20.00hrs [UK time] / 12.00 (midday) [San Francisco time] Sunday 9th June 2019
The Lancet Diabetes and Endocrinology: Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Once the embargo lifts, please use this link as the one above will be deactivated: http://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30192-5/fulltext
Embargo: 20.00hrs [UK time] / 12.00 (Midday) [San Francisco time] Sunday 9th June 2019
The Lancet Diabetes and Endocrinology: Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
Once the embargo lifts, please use this link as the one above will be deactivated: http://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30194-9/fulltext
Embargo: 22.15hrs [UK time] / 2.15pm [San Francisco time] Sunday 9th June 2019
The Lancet Diabetes and Endocrinology: Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Once the embargo lifts, please use this link as the one above will be deactivated: http://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30180-9fulltext **Please note this hyperlink will go live after the embargo lifts on the morning of Monday 10th June UK time**
Embargo: 00.30hrs [UK time] Monday 10th June / 16.30pm [San Francisco time] Sunday 9th June 2019
The Lancet: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Once the embargo lifts, please use this link as the one above will be deactivated: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext
Embargo: 00.30hrs [UK time] Monday 10th June / 16.30pm [San Francisco time] Sunday 9th June 2019
The Lancet: Dulaglutide and renal outcomes in type 2 diabetes:an exploratory analysis of the REWIND randomised, placebo-controlled trial
Once the embargo lifts, please use this link as the one above will be deactivated: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31150-X/fulltext
###
Media Contact
Lancet Press Office
[email protected]
